Already positive, the research from Deutsche Bank and its analyst Michael Kuhn still consider the stock as a Buy opportunity. The target price continues to be set at EUR 34. | April 3, 2023
UHN stands by its decision to use the drug deferiprone to treat thalassemia. Hospital officials reject allegations that money from Apotex influenced patient care.
UHN stands by its decision to use the drug deferiprone to treat thalassemia. Hospital officials reject allegations that money from Apotex influenced patient care.